Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAMPATH vs SARCLISA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
Treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy,Off-label: Multiple sclerosis (relapsing forms), Conditioning regimen for hematopoietic stem cell transplantation, Prevention of graft-versus-host disease, Treatment of solid organ transplant rejection
Treatment of multiple myeloma in combination with pomalidomide and dexamethasone in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor,Treatment of multiple myeloma in combination with carfilzomib and dexamethasone in adults with relapsed or refractory multiple myeloma after 1-3 prior lines of therapy
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Metabolism of alemtuzumab is not well defined; as a monoclonal antibody, it is expected to be catabolized into amino acids via general protein degradation pathways.
Isatuximab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via catabolic pathways. Not metabolized by CYP450 enzymes.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Not extensively characterized; negligible albumin binding due to monoclonal antibody structure.
~70% bound to plasma proteins (primarily albumin and beta-2 glycoprotein I/apoferritin).
Approximately 0.2-0.5 L/kg, indicating distribution primarily within vascular and interstitial spaces.
Vd: 0.09 L/kg (approx. 6 L), consistent with limited extravascular distribution.
Intravenous only; bioavailability 100% by IV route; no oral or IM formulation.
IV only; bioavailability 100% by IV route. Not administered orally.
No dose adjustment required for creatinine clearance (Cr Cl) ≥10 m L/min. Use with caution in severe renal impairment (Cr Cl <10 m L/min) or end-stage renal disease; no specific dose recommendations available.
No dose adjustment required for renal impairment (Cr Cl ≥15 m L/min). Not studied in end-stage renal disease (Cr Cl <15 m L/min) or dialysis; use caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), use caution; no specific dose recommendations available, and safety has not been established.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Not approved for use in pediatric patients. Safety and effectiveness in children under 18 years have not been established. No standard dosing guidelines.
Safety and efficacy not established in pediatric patients. No recommended dose.
No dose adjustment required based solely on age. However, elderly patients (≥65 years) may have higher incidence of infusion-related reactions, immunosuppression, and infections; monitor closely. Use same dosing as adults with attention to renal function.
No specific dose adjustment required. Consider comorbidities and renal function, but pharmacokinetics are similar to younger adults.
WARNING: CYTOPENIAS, INFUSION REACTIONS, AND INFECTIONS. Cytopenias: Serious, including prolonged pancytopenia and autoimmune cytopenias (hemolytic anemia, thrombocytopenia). Infusion reactions: Severe including hypotension, rigors, fever, and dyspnea; premedicate and monitor. Infections: Serious including CMV, EBV, and other opportunistic infections; monitor for reactivation.
No FDA black box warning.
Cytopenias (including autoimmune hemolytic anemia, aplastic anemia), infusion reactions, serious infections (including CMV, EBV, and other opportunistic infections), immunization with live viral vaccines not recommended, thyroid disorders, autoimmune hepatitis, and progressive multifocal leukoencephalopathy (PML).
Infusion-related reactions (may require premedication and monitoring),Neutropenia (monitor complete blood counts),Thrombocytopenia,Second primary malignancies,Interference with blood cross-matching (due to CD38 binding),Embryofetal toxicity
Patients with active systemic infections, known hypersensitivity to alemtuzumab or any of its components, and HIV-positive patients with CD4+ count < 250 cells/μL (relative).
None known.
No known food interactions. No restriction on dietary intake.
No specific food interactions. Avoid grapefruit juice if taking concurrent CYP3A4 substrates (e.g., pomalidomide) due to potential interaction. Maintain adequate hydration.
Pregnancy category C. First trimester: Anticipated risk of embryolethality and teratogenicity based on animal studies showing fetal loss and malformations. Second and third trimesters: Risk of hematologic toxicity and immunosuppression in the fetus. Alemtuzumab is an Ig G1 monoclonal antibody that crosses the placenta, with increasing transfer as gestation advances.
First trimester: Ig G1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/third trimesters: Increased placental transfer; risk of fetal cytopenias and immune suppression.
Unknown if excreted into human milk. Given the potential for serious adverse reactions in breastfed infants, including immunosuppression, breastfeeding is not recommended. No M/P ratio available.
No data on human milk excretion; M/P ratio unknown. Human Ig G enters breast milk, but degradation in infant GI tract likely limits absorption. Weigh benefits of breastfeeding against potential infant exposure.
No dose adjustment guidelines exist for pregnancy. Alemtuzumab has a long half-life (approximately 12 days) and causes prolonged immunosuppression. Use only if potential benefit justifies potential risk. No specific pharmacokinetic data in pregnancy are available.
No PK studies in pregnancy; dose adjustments not established. Isatuximab clearance may increase due to expanded plasma volume and altered Fc Rn activity, but no data to recommend specific changes. Use only if benefit outweighs risk.
Premedicate with acetaminophen and antihistamine before infusion to reduce infusion reactions. Monitor for cytopenias; growth factor support may be needed. High risk of CMV reactivation; consider prophylaxis. Lymphocyte depletion is prolonged; live vaccines contraindicated for at least 12 months after therapy.
SARCLISA (isatuximab) is an anti-CD38 monoclonal antibody for multiple myeloma. Premedicate with acetaminophen, H1 and H2 antagonists, and corticosteroids before infusion to reduce infusion-related reactions. Administer pomalidomide and dexamethasone concurrently as per protocol. Monitor for neutropenia, infusion reactions, and second primary malignancies. Do not substitute for other anti-CD38 antibodies.
You will receive premedication before each infusion to help prevent infusion-related side effects like fever, chills, or rash.,This medication lowers your white blood cell counts significantly, increasing your risk for infections. Report any fever, sore throat, or cough immediately.,You may experience low red blood cell counts (anemia) and low platelet counts, leading to fatigue or easy bruising/bleeding.,Avoid live vaccines (e.g., MMR, flu nasal spray, shingles vaccine) during treatment and for at least 12 months after.,Use effective contraception during and for 6 months after treatment; this drug can harm a fetus.,Do not receive any immunizations without consulting your doctor first.,Report any signs of infusion reaction during the infusion (e.g., chest tightness, shortness of breath, hives) to your healthcare provider immediately.
Infusion reactions: symptoms like fever, chills, rash, or difficulty breathing may occur during or after infusion; seek immediate medical attention.,Blood cell counts: this drug can decrease white blood cells, red blood cells, and platelets; report signs of infection, anemia, or bleeding.,Fetal harm: effective contraception required during and for 5 months after treatment; do not breastfeed.,Vaccinations: avoid live vaccines during treatment.,Laboratory interference: isatuximab may interfere with blood compatibility testing; inform all healthcare providers of treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAMPATH vs SARCLISA, answered by our medical review team.
CAMPATH is a Monoclonal Antibody, Antineoplastic that works by Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.. SARCLISA is a Monoclonal Antibody, Antineoplastic that works by Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAMPATH and SARCLISA depend on the specific clinical indication. These are both Monoclonal Antibody, Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAMPATH is: 12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).. The standard adult dose of SARCLISA is: 10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAMPATH and SARCLISA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAMPATH is classified as Category C. Pregnancy category C. First trimester: Anticipated risk of embryolethality and teratogenicity based on animal studies showing fetal loss and malformations. Second and third trimest. SARCLISA is classified as Category C. First trimester: IgG1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.